Quezado Z M, Banks S M, Natanson C
Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892.
Trends Biotechnol. 1995 Feb;13(2):56-63. doi: 10.1016/S0167-7799(00)88906-4.
Despite the high expectations of scientists and industry, multiple clinical trials of anti-endotoxin- and anti-cytokine-based therapies for sepsis have failed to demonstrate benefit. Indeed, in some cases, the agents used were actually harmful to patients. In retrospect, perhaps the therapeutic premises on which these therapies were based were flawed. In the future, a better understanding of sepsis should lead to the development of accurate laboratory and clinical predictors that will identify when, and which, patients can benefit from a given therapy. Much has been learned from the efforts of industry and academia and, hopefully, the search for new therapies for this lethal syndrome will continue.
尽管科学家和业界寄予厚望，但针对脓毒症的多种基于抗内毒素和抗细胞因子的治疗方法的多项临床试验均未能证明其益处。事实上，在某些情况下，所使用的药物实际上对患者有害。回顾过去，或许这些治疗方法所基于的治疗前提存在缺陷。未来，对脓毒症更深入的了解应能促成准确的实验室和临床预测指标的开发，从而确定哪些患者在何时能够从特定治疗中获益。业界和学术界的努力让我们学到了很多，希望针对这种致命综合征的新疗法探索能够继续下去。
